The New England Journal of Medicine | Research & Review Articles …
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Management of Insomnia | New England Journal of Medicine
Jul 17, 2024 · Insomnia is common and frequently occurs with other disorders. First-line cognitive behavioral therapy with or without medication can produce rapid, sustained alleviation of …
Hydrocortisone in Severe Community-Acquired Pneumonia | New …
Mar 21, 2023 · New perspectives on community-acquired pneumonia in 388 406 patients: results from a nationwide mandatory performance measurement programme in healthcare quality. …
The Emerging Threat of H5N1 to Human Health | New England …
Dec 31, 2024 · Against this background, more humans have come into contact with HPAI A(H5N1). Investigators now report in the Journal a series of human cases from the United …
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH …
Feb 7, 2024 · From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne …
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without ...
Jun 14, 2024 · New England Journal of Medicine. Volume 391 • Number 3 • July 18 ... VIC (B.C.V.C), and the Department of Neurology, University of New South Wales South Western …
Daratumumab or Active Monitoring for High-Risk Smoldering …
Dec 9, 2024 · Among the 390 enrolled patients, 194 were assigned to the daratumumab group and 196 to the active-monitoring group. With a median follow-up of 65.2 months, the risk of …
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell …
Sep 13, 2024 · Durvalumab is a selective, high-affinity human IgG1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1), blocking its interaction with programmed death 1 …
Pulmonary Arterial Hypertension | New England Journal of Medicine
Dec 15, 2021 · Other new mutations involve ATP13A3 (encoding ATPase 13A3); SOX17, which encodes SRY-box 17 and is a major risk factor for congenital heart disease–associated …
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or …